First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

The phase III, randomized, open-label ENSURE study (NCT01342965) evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China, Malaysia and the Philippines with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Patients ≥18 years...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2015-09, Vol.26 (9), p.1883-1889
Hauptverfasser:	Wu, Y-L, Zhou, C, Liam, C-K, Wu, G, Liu, X, Zhong, Z, Lu, S, Cheng, Y, Han, B, Chen, L, Huang, C, Qin, S, Zhu, Y, Pan, H, Liang, H, Li, E, Jiang, G, How, S H, Fernando, M C L, Zhang, Y, Xia, F, Zuo, Y
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Asian Continental Ancestry Group Carboplatin - adverse effects Carboplatin - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - mortality Deoxycytidine - adverse effects Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Disease-Free Survival ErbB Receptors - antagonists & inhibitors ErbB Receptors - genetics Erlotinib Hydrochloride - adverse effects Erlotinib Hydrochloride - therapeutic use Female Humans Kaplan-Meier Estimate Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - mortality Male Middle Aged Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Survival Analysis Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!